FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets
The Federal Trade Commission filed an amicus brief in an antitrust case alleging that drug manufacturer Amgen illegally acquired exclusive rights to patent applications that it shaped to cover Enbrel—a drug used to treat rheumatoid arthritis and other inflammatory…
The Federal Trade Commission filed an amicus brief in an antitrust case alleging that drug manufacturer Amgen illegally acquired exclusive rights to patent applications that it shaped to cover Enbrel—a drug used to treat rheumatoid arthritis and other inflammatory…
BELLINGS Intelligence Score: 35
Why it matters
The FTC filing an amicus brief in a biologic drug patent antitrust case signals notable regulatory scrutiny that could influence competitive dynamics and patent enforcement in a significant pharmaceutical segment, affecting market participants and credit risk assessments in healthcare lending.
Sources
FTC Competition
FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets
The Federal Trade Commission filed an amicus brief in an antitrust case alleging that drug manufacturer Amgen illegally acquired exclusive rights to patent applications that it shaped to cover Enbrel—a drug used to treat rheumatoid arthritis and other inflammatory…